Table 3.
Diagnostic biomarkers for determining the attribution of NP events to SLE |
Potential candidates: CSF and serum proteins, neuroimaging |
Novel therapies for NPSLE |
Potential targets: BBB, pro-inflammatory cytokines, microglia |
Advancing clinical trials for NPSLE. |
Potential options: drugs for non-emergent NP events (e.g. mood disorders), validate outcome measures (e.g. self-report instruments, neuroimaging for brain structure and function) |